Home » News » Awards & Advancement » Pfizer’s Karen Bien elected to board of SAFE-BioPharma

Pfizer’s Karen Bien elected to board of SAFE-BioPharma

Friday, June 29, 2012

Karen Bien, director of business technology on Pfizer’s acquisition, collaboration and divestiture team, has been elected to the board of directors of SAFE-BioPharma Association, the strategic non-profit collaboration that developed and manages the global SAFE-BioPharma digital identity and digital signature standard for the life science and healthcare sectors.

In the volunteer board position, Bien will participate in leading SAFE-BioPharma’s global expansion involving biopharmaceutical industry partners in governments, research institutions and the U.S. healthcare system.

Bien has extensive leadership experience across the pharmaceutical and healthcare industries. At Pfizer, she leads a team that provides technical services and support required for external alliances. She previously held a variety of compliance, continuous improvement and related roles at Wyeth Pharmaceuticals (now Pfizer), Siemens Medical Systems and Innovex.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!